Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

92 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Failure to validate existing clinical prediction scale for response to PD-1 monotherapy in advanced melanoma in national cohort study.
van der Kooij MK, Joosse A, Suijkerbuijk KPM, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, van den Eertwegh AJM, de Groot JWB, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Westgeest HM, Wouters MWJM, Dekkers OM, Kapiteijn E. van der Kooij MK, et al. Among authors: aarts mjb. Br J Cancer. 2023 Mar;128(5):707-710. doi: 10.1038/s41416-022-02088-8. Epub 2022 Dec 23. Br J Cancer. 2023. PMID: 36564561 Free PMC article. No abstract available.
[No title available]
[No authors listed] [No authors listed] PMID: 36319872
Systemic Therapy in Advanced Nodular Melanoma versus Superficial Spreading Melanoma: A Nation-Wide Study of the Dutch Melanoma Treatment Registry.
Rauwerdink DJW, van Doorn R, van der Hage J, Van den Eertwegh AJM, Haanen JBAG, Aarts M, Berkmortel F, Blank CU, Boers-Sonderen MJ, De Groot JWB, Hospers GAP, de Meza M, Piersma D, Van Rijn RS, Stevense M, Van der Veldt A, Vreugdenhil G, Wouters MWJM, Suijkerbuijk K, van der Kooij M, Kapiteijn E. Rauwerdink DJW, et al. Cancers (Basel). 2022 Nov 19;14(22):5694. doi: 10.3390/cancers14225694. Cancers (Basel). 2022. PMID: 36428787 Free PMC article.
Cemiplimab in locally advanced or metastatic cutaneous squamous cell carcinoma: prospective real-world data from the DRUG Access Protocol.
Verkerk K, Geurts BS, Zeverijn LJ, van der Noort V, Verheul HMW, Haanen JBAG, van der Veldt AAM, Eskens FALM, Aarts MJB, van Herpen CML, Jalving M, Gietema JA, Devriese LA, Labots M, Barjesteh van Waalwijk van Doorn-Khosrovani S, Smit EF, Bloemendal HJ. Verkerk K, et al. Among authors: aarts mjb. Lancet Reg Health Eur. 2024 Mar 5;39:100875. doi: 10.1016/j.lanepe.2024.100875. eCollection 2024 Apr. Lancet Reg Health Eur. 2024. PMID: 38464480 Free PMC article.
Improving survival in advanced melanoma patients: a trend analysis from 2013 to 2021.
van Not OJ, van den Eertwegh AJM, Haanen JB, Blank CU, Aarts MJB, van Breeschoten J, van den Berkmortel FWPJ, de Groot JB, Hospers GAP, Ismail RK, Kapiteijn E, Bloem M, De Meza MM, Piersma D, van Rijn RS, Stevense-den Boer MAM, van der Veldt AAM, Vreugdenhil G, Boers-Sonderen MJ, Blokx WAM, Wouters MWJM, Suijkerbuijk KPM. van Not OJ, et al. Among authors: aarts mjb. EClinicalMedicine. 2024 Feb 12;69:102485. doi: 10.1016/j.eclinm.2024.102485. eCollection 2024 Mar. EClinicalMedicine. 2024. PMID: 38370537 Free PMC article.
Gene-expression-based T-Cell-to-Stroma Enrichment (TSE) score predicts response to immune checkpoint inhibitors in urothelial cancer.
Rijnders M, Nakauma-González JA, Robbrecht DGJ, Gil-Jimenez A, Balcioglu HE, Oostvogels AAM, Aarts MJB, Boormans JL, Hamberg P, van der Heijden MS, Szabados BE, van Leenders GJLH, Mehra N, Voortman J, Westgeest HM, de Wit R, van der Veldt AAM, Debets R, Lolkema MP. Rijnders M, et al. Among authors: aarts mjb. Nat Commun. 2024 Feb 14;15(1):1349. doi: 10.1038/s41467-024-45714-0. Nat Commun. 2024. PMID: 38355607 Free PMC article.
A prediction model for response to immune checkpoint inhibition in advanced melanoma.
van Duin IAJ, Verheijden RJ, van Diest PJ, Blokx WAM, El-Sharouni MA, Verhoeff JJC, Leiner T, van den Eertwegh AJM, de Groot JWB, van Not OJ, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Haanen JBAG, Hospers GAP, Piersma D, van Rijn RS, van der Veldt AAM, Vreugdenhil G, Wouters MWJM, Stevense-den Boer MAM, Boers-Sonderen MJ, Kapiteijn E, Suijkerbuijk KPM, Elias SG. van Duin IAJ, et al. Among authors: aarts mjb. Int J Cancer. 2024 May 15;154(10):1760-1771. doi: 10.1002/ijc.34853. Epub 2024 Jan 31. Int J Cancer. 2024. PMID: 38296842
Internet-based cognitive rehabilitation for working cancer survivors: results of a multicenter randomized controlled trial.
Klaver KM, Duijts SFA, Geusgens CAV, Kieffer JM, Agelink van Rentergem J, Hendriks MP, Nuver J, Marsman HA, Poppema BJ, Oostergo T, Doeksen A, Aarts MJB, Ponds RWHM, van der Beek AJ, Schagen SB. Klaver KM, et al. Among authors: aarts mjb. JNCI Cancer Spectr. 2024 Jan 4;8(1):pkad110. doi: 10.1093/jncics/pkad110. JNCI Cancer Spectr. 2024. PMID: 38273712 Free PMC article. Clinical Trial.
BRAF/MEK inhibitor rechallenge in advanced melanoma patients.
Van Not OJ, van den Eertwegh AJM, Haanen JB, van Rijn RS, Aarts MJB, van den Berkmortel FWPJ, Blank CU, Boers-Sonderen MJ, de Groot JWWB, Hospers GAP, Kapiteijn E, Bloem M, Piersma D, Stevense-den Boer M, Verheijden RJ, van der Veldt AAM, Wouters MWJM, Blokx WAM, Suijkerbuijk KPM. Van Not OJ, et al. Among authors: aarts mjb. Cancer. 2024 May 1;130(9):1673-1683. doi: 10.1002/cncr.35178. Epub 2024 Jan 10. Cancer. 2024. PMID: 38198485
92 results